InMode Ltd. Receives Acquisition Proposal from M.N. Business Strategy

In a significant development for the healthcare technology sector, InMode Ltd. (Nasdaq: INMD), a prominent provider of innovative medical technologies, announced on June 24, 2026, that its Board of Directors received an unsolicited proposal from M.N. Business Strategy, Ltd. This group, which includes co-founder and CEO Moshe Mizrahy, is looking to acquire all outstanding ordinary shares of InMode not currently owned by them or their affiliates.

The proposal suggests a cash purchase price of $16.20 per share, signaling M.N. Business Strategy's intent to gain complete control over InMode. In response to this unsolicited offer, InMode's Board has initiated the formation of a special committee composed entirely of independent directors. This committee is charged with the crucial task of assessing the proposal, ensuring that all evaluations are in line with their fiduciary duties and the best interests of the company and its shareholders.

While the board has taken the necessary first step by forming the special committee, there are no guarantees this evaluation will lead to a finalized transaction or any other strategic direction for the company. Furthermore, the specifics concerning the potential timelines or conditions of any resultant agreements remain uncertain.

InMode has carved a niche for itself in the global market, being known for its development, manufacturing, and marketing of devices that utilize cutting-edge radiofrequency (RF) technology. Its products have garnered acceptance in various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. The company continues to strive towards enabling emerging surgical procedures and enhancing existing treatments through its innovative technologies.

In light of this unsolicited proposal, stakeholders are keenly observing the proceedings of the special committee. The implications of a merger could be significant, impacting not just the company’s operational strategy but also its overall presence in the evolving healthcare technology landscape.

InMode’s leadership remains tight-lipped on the details or progress of the committee's review, indicating they will refrain from commentary unless legally required to provide updates. This approach is standard in such acquisition evaluations, as companies must navigate various regulatory landscapes to ensure compliance with laws.

Given the specialized nature of InMode’s offerings and the strategic intent of M.N. Business Strategy, the forthcoming assessment will undoubtedly hold considerable weight in shaping the path ahead for InMode. As the landscape of medical technology continues to advance, the decision taken by the special committee will not only affect the company’s shareholders but could also ripple through the broader market.

As the evaluation unfolds, observers remain alert to any new developments that may emerge from this situation. The potential merger is indicative of the ongoing trends towards consolidation within the medical technology sector, reflecting the increasing pressures and market dynamics that influence such significant corporate decisions.

In conclusion, the unsolicited acquisition proposal represents a critical juncture for InMode Ltd. as it navigates the complexities of this potential transaction. All eyes will be on the special committee's findings and the strategic choices the company makes in response to this offer.